Innoventric Secures $28.5M to Expand Transcatheter Tricuspid Valve Treatment
What You Should Know:
– Innoventric, a leader in transcatheter tricuspid regurgitation (TR) treatment, today announced a $28.5 million Series B funding round to advance its revolutionary cross-caval technology, bringing the total funds raised since inception…
Continue Reading